Latest Conference Articles

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab, respectively, in branch retinal vein occlusion and central retinal vein occlusion.

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.

In conversation with Ophthalmology Times Europe, Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis.

Dr. Carl Regillo provided an overview of topline results and a deep dive into subgroup analyses of DAVIO 2 trial data.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants.

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The afternoon sessions promise to be engaging and informative in this virtual conference.

This meeting, scheduled for Saturday, February 3, 2024, is a 1-day virtual event sponsored by the Bascom Palmer Eye Institute, Miami, University of Miami Health System.

Leanne Clevenger, MD, described a case that highlights varying approaches and protocols for addressing a complex case of retinal detachment repair in a patient with trauma to the globe.

David Hutton of Ophthalmology Times talks with Adrienne Scott, MD, FASRS, about her part in a panel discussion detailing emerging therapies for AMD.

David Hutton of Ophthalmology Times talks with Sunir Garg, MD about his surgical video panel at this year's Retina Fellows Forum.

Allen Ho, MD, FACS, FASRS, will make a presentation at the meeting, to be held virtually on February 3.

Gather, participate, learn, socialize

The 24th annual Retina Fellows Forum will take place on January 25 and 26, 2024 in Chicago at the Westin Chicago River North hotel.

Sophie Bakri, MD, spoke with the Ophthalmology Times team about her presentation at this year's American Academy of Ophthalmology meeting titled, "Real world outcomes and treatment patterns with faricimab and AMD FA retina."

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Mathew MacCumber, MD, PhD, FASRS, spoke with Modern Retina about his presentation at the recent Retina Society meeting in New York City titled, "0.19 mg Fluocinolone Acetonide (FAc) Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study."

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Charles Wykoff, MD, PhD, spoke with the Ophthalmology Times team about the GALE study looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.